SESSION 2 | 13:45 – 14:20
VEGF related and other retinal indications
Moderators: Anat Loewenstein / Francesco Bandello
13:45
Sascha Fauser, Roche — Roche’s Commitment to Ophthalmology – building an innovative pipeline
13:50
Julian Smith, Abbvie — A commitment to addressing unmet needs in retinal diseases
13:55
Russell Trenary, Outlook Therapeutics — Redefining the Standard of Care for Bevacizumab as an Anti VEGF for Retina
14:00
Ramiro Ribeiro, Eyepoint Pharmaceuticals — Committed to developing therapeutics to help improve the lives of patients with serious retinal diseases
14:05
Nadia K Waheed, Ocular Therapeutix — Changing the future paradigm for the management of retinal vascular diseases
14:10
Panel Discussion — Anat Loewenstein, Francesco Bandello, Sascha Fauser, Julian Smith, Russel Trenary, Ramiro Ribeiro & Nadia K Waheed
